Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML TreatmentErin Clapper(Griffith University), Kathryn F. Tonissen(Griffith University)AntioxidantsMarch 3, 202010.3390/antiox9030207Cited by 17SaveCiteExport RISWatch citationsRelated PapersThe Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia|Hemato|2021|0